Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

SHSE:600613 Stock Report

Market Cap: CN¥3.5b

Shanghai Shenqi Pharmaceutical Investment Management Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Feng Bin

Chief executive officer

CN¥480.3k

Total compensation

CEO salary percentagen/a
CEO tenure13.4yrs
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

There May Be Reason For Hope In Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Disappointing Earnings

Nov 06
There May Be Reason For Hope In Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Disappointing Earnings

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) 26% Share Price Surge Not Quite Adding Up

Oct 21
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) 26% Share Price Surge Not Quite Adding Up

Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem

May 06
Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem

Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking

Apr 17
Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking

CEO

Feng Bin (52 yo)

13.4yrs

Tenure

CN¥480,300

Compensation

Mr. Feng Bin is a Director of Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. (formerly known as Shanghai Wingsung Investment Management Co., Ltd.) and serves as its General Manager since Jun...